A detailed history of Checkpoint Capital L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 663,381 shares of RYTM stock, worth $39.5 Million. This represents 17.24% of its overall portfolio holdings.

Number of Shares
663,381
Previous 922,100 28.06%
Holding current value
$39.5 Million
Previous $37.9 Billion 8.21%
% of portfolio
17.24%
Previous 22.82%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.81 - $55.0 $10.6 Million - $14.2 Million
-258,719 Reduced 28.06%
663,381 $34.8 Billion
Q2 2024

Aug 14, 2024

BUY
$35.41 - $44.37 $3.42 Million - $4.29 Million
96,600 Added 11.7%
922,100 $37.9 Billion
Q1 2024

May 15, 2024

BUY
$39.12 - $52.44 $3.74 Million - $5.01 Million
95,500 Added 13.08%
825,500 $35.8 Billion
Q4 2023

Feb 14, 2024

BUY
$21.39 - $49.64 $15.6 Million - $36.2 Million
730,000 New
730,000 $33.6 Billion

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.31B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Checkpoint Capital L.P. Portfolio

Follow Checkpoint Capital L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Checkpoint Capital L.P., based on Form 13F filings with the SEC.

News

Stay updated on Checkpoint Capital L.P. with notifications on news.